We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Randomized Implementation of Primary HPV Testing in the Organized Screening for Cervical Cancer in Stockholm

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01511328
Recruitment Status : Active, not recruiting
First Posted : January 18, 2012
Last Update Posted : January 28, 2022
Region Stockholm
Information provided by (Responsible Party):
Joakim Dillner, Karolinska Institutet

Brief Summary:
The purpose is to evaluate whether implementation of primary human papillomavirus (HPV) screening in the screening programme for cervical cancer improves the programme in terms of better cancer protection and better cost efficiency.

Condition or disease Intervention/treatment Phase
High-grade Cervical Intraepithelial Neoplasia Other: HPV testing Not Applicable

Detailed Description:

Primary HPV screening is a method with higher sensitivity than cytology for detection of high-grade cervical intraepithelial neoplasia, which is the precursor of cervical cancer. In particular, HPV test is a better test for revealing adenocarcinomas, since these cancers often show a normal cytology.

Cervical cancer screening at age 60:

Cytology is less effective in older women, and screening with cytology in women over 60 has no documented effect. Today a large part of cervical cancer develop in women older than 60, to whom no screening is offered. The prevalence of HPV is around 4% in this age group. Since we know that testing negative for HPV gives a better long-term protection against cervical cancer compared to cytology, primary screening for HPV in 60-year old women would give a longer lasting protection in this high-risk group compared with today.

Cervical cancer screening at age 30-40:

HPV screening is most cost effective above 35 years of age. The reason for this is that HPV is less prevalent at age 35 than in younger women and also because cervical cancer seldom develops before this age. Since the HPV test has a negative predictive value (NPV) of almost 100% this could lead to longer screening intervals, which would be improve cost-effectiveness.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 270000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Randomized Implementation of Primary Human Papillomavirus (HPV) Testing in the Organized Screening for Cervical Cancer in Stockholm
Actual Study Start Date : January 1, 2012
Actual Primary Completion Date : June 30, 2017
Estimated Study Completion Date : December 2031

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cervical Cancer

Arm Intervention/treatment
Experimental: HPV testing
Women randomised to this arm get primary HPV testing
Other: HPV testing
Testing for Human Papilloma Virus

No Intervention: cytology
women included follow the standard procedure with primary cytology

Primary Outcome Measures :
  1. Cervical intraepithelial neoplasia 2+ (CIN2+) [ Time Frame: first evaluation, the 1 of january 2013 ]
    The number of women with CIN2+ detected by primary HPV testing will be compared with the number of women with CIN2+ detected by primary cytology

Secondary Outcome Measures :
  1. Cost for the two different diagnostic procedures [ Time Frame: first evaluation, 1 of January 2013 ]
    The cost for the new procedure with HPV test in primary screening will be compared to the routine procedure with primary cytology

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 64 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Women between the age 30 and 64 years resident in the Stockholm-Gotland region. No exclusion criteria.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01511328

Layout table for location information
Karolinska University Hospital
Stockholm, Sweden, 141 86
Sponsors and Collaborators
Karolinska Institutet
Region Stockholm
Layout table for investigator information
Principal Investigator: Joakim Dillner, MD, PhD Karolinska Institutet
Publications of Results:
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Joakim Dillner, MD, PhD, Karolinska Institutet
ClinicalTrials.gov Identifier: NCT01511328    
Other Study ID Numbers: SLL-KI-HPV
First Posted: January 18, 2012    Key Record Dates
Last Update Posted: January 28, 2022
Last Verified: January 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Joakim Dillner, Karolinska Institutet:
HPV testing
Primary screening
Cervical Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Neoplasms
Cervical Intraepithelial Neoplasia
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Carcinoma in Situ
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type